Standard essential patents (SEPs) and fair, reasonable and non-discriminatory (FRAND) licensing terms remain hotly debated topics within antitrust circles as regulators around the world stake out…
This case relates to the interplay between EU competition law and the pharmaceutical regulatory regime. It arose in the context of an arrangement in which Genentech licensed Bevacizumab to one…
The views expressed are exclusively the authors and do not necessarily reflect the opinion of CADE.
I. Introduction
The Brazilian Competition Authority (known as “CADE” – Conselho Administrativo de…
I. INTRODUCTION
In June 2015, Canada’s Competition Bureau released its updated draft of the Intellectual Property Enforcement Guidelines ("Draft IPEGs") for public review and consultation. The Draft…
On 11 December 2014 Google announced that it would be closing down Google News in Spain. The decision came after the introduction of new copyright legislation supported by the Association of Editors…
Pushing people around is the flavour of the month right now. Indeed, both companies and regulators seem to be going in for it.
Take the music industry, for instance. The US entertainment giant AEG…
There have been two key recent developments in the U.S. relating to the legal dispute over patent settlements including so-called “reverse payments.” First, the U.S. Supreme Court has agreed to…
On 16 July 2012, a U.S. appeals court issued a decision holding that pharmaceutical patent settlements that restrict generic entry and contain a payment to the generic company are presumptively…
The U.S. Supreme Court recently issued a decision that provides generic pharmaceutical manufacturers with the ability to challenge the “use codes” listed by brand name manufacturers in filings made…
